03
Jun
Relapsed/refractory the term “relapsed” refers to disease that reappears or grows again after a period of remission. Refractory lymphoma is lymphoma that has not responded to initial treatment or the lymphoma gets worse or stays the same.
1 nhl comprises a group of clinically and biologically diverse diseases, which range from indolent to aggressive clinical courses.
Refractory non hodgkins lymphoma. Salvage therapy for relapsed or refractory. Follicular lymphoma (fl), marginal zone lymphoma (mzl) and mantle cell lymphoma (mcl) are. It accounts for approximately 22% of all lymphomas diagnosed worldwide.
Currently, there are limited options for the treatment of relapsed or refractory indolent fl after two or more lines of therapy. We also know from research, that not everyone responds the same way to various treatments. Refractory disease may be disease that is getting worse or staying the same.
Relapsed/refractory the term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long. To appraise the clinical and cost effectiveness of mosunetuzumab within its marketing authorisation for treating relapsed or refractory follicular lymphoma.
Patients who do not experience a complete disappearance or remission of their cancer following a complete course of chemotherapy treatment Drugs used for refractory and relapsed nhl Listing a study does not mean it has been evaluated by the u.s.
Refractory lymphoma is lymphoma that has not responded to initial treatment or the lymphoma gets worse or stays the same. Patients with relapsed nhl can be divided into two broad categories: 1 nhl comprises a group of clinically and biologically diverse diseases, which range from indolent to aggressive clinical courses.
This treatment approach appears to offer superior results. The wide range of response rates (between 32% and 84% reported in other series) likely reflects relatively small sample sizes and imbalances of this and other prognostic factors.